MX392040B - Estandares de antigeno prostatico y sus usos. - Google Patents

Estandares de antigeno prostatico y sus usos.

Info

Publication number
MX392040B
MX392040B MX2017012320A MX2017012320A MX392040B MX 392040 B MX392040 B MX 392040B MX 2017012320 A MX2017012320 A MX 2017012320A MX 2017012320 A MX2017012320 A MX 2017012320A MX 392040 B MX392040 B MX 392040B
Authority
MX
Mexico
Prior art keywords
prostate
antigen standards
prostate antigen
standards
aspects
Prior art date
Application number
MX2017012320A
Other languages
English (en)
Other versions
MX2017012320A (es
Inventor
Christina Higgins
Vincent Linder
Original Assignee
Opko Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Diagnostics Llc filed Critical Opko Diagnostics Llc
Publication of MX2017012320A publication Critical patent/MX2017012320A/es
Publication of MX392040B publication Critical patent/MX392040B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a métodos mejorados para predecir si una biopsia de tejido prostático obtenida de un sujeto contendrá cáncer de próstata detectable; en algunas modalidades, la descripción proporciona estándares de antígeno prostático mejorados para cuantificar niveles de antígenos de próstata.
MX2017012320A 2015-03-27 2016-03-25 Estandares de antigeno prostatico y sus usos. MX392040B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562139365P 2015-03-27 2015-03-27
PCT/US2016/024149 WO2016160545A1 (en) 2015-03-27 2016-03-25 Prostate antigen standards and uses thereof

Publications (2)

Publication Number Publication Date
MX2017012320A MX2017012320A (es) 2018-01-18
MX392040B true MX392040B (es) 2025-03-21

Family

ID=56975150

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012320A MX392040B (es) 2015-03-27 2016-03-25 Estandares de antigeno prostatico y sus usos.
MX2022002138A MX2022002138A (es) 2015-03-27 2017-09-26 Estandares de antigeno prostatico y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022002138A MX2022002138A (es) 2015-03-27 2017-09-26 Estandares de antigeno prostatico y sus usos.

Country Status (15)

Country Link
US (1) US11921115B2 (es)
EP (2) EP3253800B1 (es)
JP (1) JP6749337B2 (es)
CN (1) CN107406510B (es)
DE (1) DE202016008692U1 (es)
DK (1) DK3253800T3 (es)
ES (1) ES2867798T3 (es)
HU (1) HUE055020T2 (es)
IL (1) IL254412B (es)
MX (2) MX392040B (es)
PL (1) PL3253800T3 (es)
PT (1) PT3253800T (es)
TW (1) TWI698639B (es)
UA (1) UA124522C2 (es)
WO (1) WO2016160545A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152417B1 (en) 2007-05-04 2018-07-11 Opko Diagnostics, LLC Device and method for analyses in microfluidic systems
EP2391451B1 (en) 2009-02-02 2018-09-12 Opko Diagnostics, LLC Structures for controlling light interaction with microfluidic devices
MX362555B (es) 2012-03-05 2019-01-24 Oy Arctic Partners Ab Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica.
DE202015009668U1 (de) 2014-03-28 2019-01-21 Opko Diagnostics, Llc Zusammensetzungen zur Diagnose von Prostatakrebs
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
DE102015105979A1 (de) 2015-04-20 2016-10-20 Mankiewicz Gebr. & Co. Gmbh & Co. Kg Verbesserte Beschichtungssysteme, deren Verwendung zur Beschichtung von Bauteilen sowie damit beschichtete Bauteile für Windkraftanlagen
US10852310B2 (en) 2015-12-11 2020-12-01 Opko Diagnostics, Llc Fluidic systems involving incubation of samples and/or reagents
EP3397387B1 (en) 2015-12-29 2021-03-24 Opko Diagnostics, LLC Fluid collection device and related methods
US11662564B2 (en) 2017-06-15 2023-05-30 Shenzhen Prs Limited Paraffin shield coating for microscope slide
US12313834B2 (en) 2017-06-15 2025-05-27 Shenzhen Prs Limited Paraffin shield coating for microscope slide
CN110753846B (zh) * 2017-06-15 2024-03-26 深圳市诺高实验器材有限公司 免疫组织化学抗原成像标尺外推方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
ATE263962T1 (de) 1993-10-28 2004-04-15 I Stat Corp Vorrichtung zur abnahme und einleitung von flüssigkeitsproben
US5599677A (en) 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
KR19990036069A (ko) 1995-08-03 1999-05-25 이.에이치. 리링크 진단 장치
JP3645023B2 (ja) * 1996-01-09 2005-05-11 富士写真フイルム株式会社 試料分析方法、検量線の作成方法及びそれを用いる分析装置
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
WO1997039351A1 (en) 1996-04-12 1997-10-23 Carter Herbert B Novel methods for the prediction and early detection of prostatic adenocarcinoma
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5945289A (en) 1996-12-20 1999-08-31 Lehrer; Steven Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
SE9704934D0 (sv) 1997-12-30 1997-12-30 Pharmacia & Upjohn Diag Ab Analysförfarande med tillsättning i två eller flera positioner
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
FR2780791B1 (fr) 1998-07-03 2000-09-01 Bio Merieux Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
US6551778B1 (en) 1999-01-28 2003-04-22 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7211397B2 (en) 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6136549A (en) 1999-10-15 2000-10-24 Feistel; Christopher C. systems and methods for performing magnetic chromatography assays
FI20002127A0 (fi) * 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
AU2001297014A1 (en) 2000-10-10 2002-04-22 Aviva Biosciences Corporation An integrated biochip system for sample preparation and analysis
CA2428011A1 (en) 2000-11-20 2002-06-13 Eastern Virginia Medical School Methods and devices for the quantitative detection of prostate specific membrane antigen and other prostatic markers
AU2002362447A1 (en) 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
US7258837B2 (en) 2001-12-05 2007-08-21 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
US20050272052A1 (en) 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
JPWO2003100425A1 (ja) 2002-05-28 2005-11-04 株式会社常光 免疫学的クロマトグラフ法の試験紙片の読み取り定量装置
DK1540010T3 (da) 2002-08-06 2010-07-26 Univ Johns Hopkins Anvendelse af biomarkører til påvisning af ovariecancer
US20040115794A1 (en) 2002-12-12 2004-06-17 Affymetrix, Inc. Methods for detecting transcriptional factor binding sites
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
US7461048B2 (en) 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
US20050118061A1 (en) 2003-11-28 2005-06-02 Sysmex Corporation Analyzer, assay cartridge and analyzing method
EP1691924B1 (en) 2003-12-10 2016-09-14 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin A modular biochip assembly
CA2564609C (en) 2003-12-31 2014-02-11 President And Fellows Of Harvard College Assay device and method
EP1776181B1 (en) 2004-01-26 2013-09-11 The President and Fellows of Harvard College Fluid delivery system and method
US8030057B2 (en) 2004-01-26 2011-10-04 President And Fellows Of Harvard College Fluid delivery system and method
TW200538734A (en) 2004-03-12 2005-12-01 Aureon Biosciences Corp Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
EP1747466A2 (en) 2004-05-11 2007-01-31 Baylor College Of Medicine Method to predict prostate cancer
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
WO2006022895A2 (en) 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
AU2005287074A1 (en) 2004-09-17 2006-03-30 Ciphergen Biosystems, Inc. Biomarkers for breast cancer
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
WO2006122311A2 (en) 2005-05-11 2006-11-16 The Trustees Of The University Of Pennsylvania Microfluidic chip
US20070065954A1 (en) 2005-09-15 2007-03-22 Minoru Taya Surface plasmon resonance biosensor system for detection of antigens and method for determining the presence of antigens
AU2007231487B2 (en) 2006-03-24 2014-01-09 Phenomenome Discoveries Inc. Biomarkers useful for diagnosing prostate cancer, and methods thereof
AU2007271232A1 (en) 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
CN1973778A (zh) 2006-12-08 2007-06-06 南京大学 胃癌术后严重并发症风险度的预测方法
US9182400B2 (en) 2006-12-22 2015-11-10 Phadia Ab Prostate kallikrein allergen
EP2152417B1 (en) 2007-05-04 2018-07-11 Opko Diagnostics, LLC Device and method for analyses in microfluidic systems
CA2686954A1 (en) 2007-05-08 2008-11-20 Picobella Llc Methods for diagnosing and treating prostate and lung cancer
CN101329343A (zh) 2007-06-19 2008-12-24 天津迪爱盟生物技术有限公司 新一代早期诊断前列腺癌试剂盒及其制备方法和检测方法
WO2009029550A2 (en) * 2007-08-24 2009-03-05 Singulex, Inc. Highly sensitive system and methods for analysis of prostate specific antigen (psa)
CN101377500A (zh) * 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 游离前列腺特异性抗原化学发光免疫分析测定试剂盒及其制备方法
JP5272011B2 (ja) 2007-10-22 2013-08-28 セントビンセンツ ホスピタル シドニー リミテッド 予後判定の方法
WO2009085196A1 (en) 2007-12-21 2009-07-09 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
JP5028697B2 (ja) 2008-02-18 2012-09-19 富士フイルム株式会社 吸引シリンジ及び内視鏡用吸引シリンジ
CA2724433A1 (en) 2008-05-14 2009-11-19 Eth Zuerich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
FR2934698B1 (fr) 2008-08-01 2011-11-18 Commissariat Energie Atomique Procede de prediction pour le pronostic ou le diagnostic ou la reponse therapeutique d'une maladie et notamment du cancer de la prostate et dispositif permettant la mise en oeuvre du procede.
US8386187B2 (en) 2008-10-20 2013-02-26 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
CA2745961A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
WO2010080115A2 (en) 2008-12-18 2010-07-15 Claros Diagnostics, Inc. Improved reagent storage in microfluidic systems and related articles and methods
US20100168621A1 (en) 2008-12-23 2010-07-01 Neville Thomas B Methods and systems for prostate health monitoring
US20120022793A1 (en) 2009-01-19 2012-01-26 Miraculins, Inc. Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population
EP2391451B1 (en) 2009-02-02 2018-09-12 Opko Diagnostics, LLC Structures for controlling light interaction with microfluidic devices
JP2010243406A (ja) 2009-04-08 2010-10-28 F Hoffmann La Roche Ag Ａｆｐおよびｐｉｖｋａ−ｉｉの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法
SG175832A1 (en) 2009-05-01 2011-12-29 Genomic Health Inc Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
CN102483416A (zh) 2009-06-04 2012-05-30 梅坦诺米克斯保健有限公司 诊断前列腺癌的工具和方法
WO2011027310A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
KR101141190B1 (ko) 2009-10-19 2012-06-13 중앙대학교 산학협력단 전립선암에 대한 바이오마커 및 이를 이용한 전립선암 진단
BR112012022917A2 (pt) 2010-03-11 2017-01-10 Pfizer anticorpos com ligação a antígeno dependente de ph
CA3016653C (en) 2010-04-16 2024-01-02 Opko Diagnostics, Llc Feedback control in microfluidic systems
WO2012029080A1 (en) 2010-08-30 2012-03-08 Decode Genetics Ehf Sequence variants associated with prostate specific antigen levels
BRPI1100857A2 (pt) 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9594086B2 (en) 2011-03-22 2017-03-14 The Johns Hopkins University Biomarkers for aggressive prostate cancer
WO2012170776A2 (en) * 2011-06-09 2012-12-13 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
US9638706B2 (en) 2011-07-21 2017-05-02 Wako Pure Chemical Industries, Ltd. Standard solution for use in analysis of amino acid in plasma
LT2771037T (lt) 2011-10-28 2017-01-25 Fredax Ab Terapiniai agentai ir jų panaudojimas
WO2013106778A2 (en) * 2012-01-13 2013-07-18 Iris International, Inc. Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
MX362555B (es) * 2012-03-05 2019-01-24 Oy Arctic Partners Ab Metodos y aparatos para predecir riesgo de cancer de prostata y volumen de glandula prostatica.
RU2014150777A (ru) 2012-05-16 2016-07-10 Пхадиа Аб Способ индикации наличия или отсутствия рака предстательной железы
AU2013284448B2 (en) 2012-06-27 2019-04-18 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
CN102818892B (zh) 2012-08-16 2015-02-18 北京恩济和生物科技有限公司 一种前列腺特异性抗原检测试剂盒及其制备方法
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
MY182773A (en) 2012-11-20 2021-02-05 Phadia Ab Method for indicating a presence or non-presence of aggressive prostate cancer
ES2694409T3 (es) 2012-11-20 2018-12-20 Phadia Ab Método de pronóstico para individuos con cáncer de próstata
CN105980404B (zh) 2013-11-19 2021-01-12 弗雷达克斯有限责任公司 人源化抗激肽释放酶-2抗体
EP4220170A3 (en) 2014-03-11 2023-12-13 Phadia AB Method for detecting a solid tumor cancer
DE202015009668U1 (de) 2014-03-28 2019-01-21 Opko Diagnostics, Llc Zusammensetzungen zur Diagnose von Prostatakrebs
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2016145331A1 (en) 2015-03-12 2016-09-15 Thermo Finnigan Llc Methods for data-dependent mass spectrometry of mixed biomolecular analytes
EP3247387A4 (en) 2015-04-29 2018-09-12 Opko Diagnostics, LLC Compositions and methods for active surveillance of prostate cancer
US20190072555A1 (en) 2017-08-14 2019-03-07 Opko Diagnostics, Llc Multiplex assays for evaluating prostate cancer status
WO2019221930A1 (en) 2018-05-16 2019-11-21 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes

Also Published As

Publication number Publication date
IL254412A0 (en) 2017-11-30
TWI698639B (zh) 2020-07-11
UA124522C2 (uk) 2021-10-05
PL3253800T3 (pl) 2021-08-23
HUE055020T2 (hu) 2021-11-29
CN107406510A (zh) 2017-11-28
DK3253800T3 (da) 2021-05-31
EP3253800B1 (en) 2021-03-03
WO2016160545A1 (en) 2016-10-06
JP2018511055A (ja) 2018-04-19
DE202016008692U1 (de) 2019-02-13
EP3318878A3 (en) 2018-07-11
US20240159758A1 (en) 2024-05-16
EP3318878A2 (en) 2018-05-09
CA2979559A1 (en) 2016-10-06
EP3253800A4 (en) 2018-11-07
PT3253800T (pt) 2021-04-28
JP6749337B2 (ja) 2020-09-02
MX2017012320A (es) 2018-01-18
US11921115B2 (en) 2024-03-05
CN107406510B (zh) 2022-02-18
ES2867798T3 (es) 2021-10-20
US20170370938A9 (en) 2017-12-28
TW201643429A (zh) 2016-12-16
IL254412B (en) 2021-01-31
MX2022002138A (es) 2022-03-17
US20160282349A1 (en) 2016-09-29
EP3253800A1 (en) 2017-12-13

Similar Documents

Publication Publication Date Title
MX392040B (es) Estandares de antigeno prostatico y sus usos.
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
MX2016012667A (es) Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
UY34815A (es) Anticuerpos biespecíficos y sus métodos de uso
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
CR20140441A (es) Anticuerpos anti-lgr5 e inmunoconjugados
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX387719B (es) Biomarcadores de la enfermedad del hígado graso no alcohólico (nafld) y la esteatohepatitis no alcohólica (nash) y usos de estos.
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
MX2019001026A (es) Anticuerpos de antihemaglutinina y metodos de uso.
EP3100046A4 (en) Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)
EP4513187A3 (en) Methods of detecting prostate cancer
MX374415B (es) Composiciones y métodos para identificar un riesgo de cáncer en un sujeto.
MX2019004940A (es) Uso de beta-catenina como un biomarcador para el tratamiento de canceres que usan el anticuerpo anti-dkk-1.
MX350807B (es) Composiciones y metodos para el analisis de cancer de prostata.
MA40636A (fr) Procédés pour détecter le cancer de la prostate
EA202092450A2 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей